dosing compounded semaglutide FDA alerts health care providers, compounders and patients of errors associated with injectable products Troubling Findings in Study of

Ozempic is a GLP-1 medication originally developed to help manage type 2 diabetes, but it has also been shown to support weight loss by regulating appetite and slowing digestion

The FDA closely monitors 503A compounders to ensure sterility, potency, and purity equivalent to mass-manufactured medications

Highest dose, obesity trial obesity-plus-diabetes trial (treatment-policy estimand): Semaglutide: 14.9% (STEP 1) 9.6% (STEP 2), a 5.3 point gap Tirzepatide: 20.9% (SURMOUNT-1) 14.7% (SURMOUNT-2), a 6.2 point gap Retatrutide: 25.0% (TRIUMPH-1) 20.8% (TRIUMPH-2 only efficacy-estimand currently reported so true gap is larger) It's still unclear the reason why we observe less weight loss in those with type 2 diabetes

Metabolic effects of tesamorelin, a growth hormone-releasing factor, in patients with HIV-associated abdominal fat accumulation: a randomized, double-blind, placebo-controlled trial